Cancer Subtypes of Breast Carcinoma with Micropapillary and Mucinous Component Based on Immunohistochemical Profile
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Background: Micropapillary carcinoma (MPC) is known to have a worse prognosis than the other subtypes of breast cancer. Occasionally, MPC is observed in association with invasive ductal carcinoma not otherwise specified (IDC NOS), as well as mucinous carcinoma. Methods: We examined the immunohistochemical expression of an estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) in 127 cases of surgically resected MPC or IDC NOS with MPC. Further, we classified these cases based on their immunohistochemical profile. Results: Among the IDC NOS with MPC cases, 47 were luminal A (62.7%), 10 were luminal B (13.3%), and 9 were HER2 (12.0%). The MPC cases included 4 luminal A (50.0%), 2 luminal B (25.0%) and 1 HER2 (12.5%) subtypes. Of the mucinous carcinomas with MPC, 4 were grouped as luminal A (57.1%), 1 as luminal B (14.3%), and 2 as HER2 (28.6%) subtypes. However, among the mucinous carcinomas, 33 were categorized as luminal A (89.2%), 3 as luminal B (8.1%), and 1 as HER2 (2.7%) subtype, indicating a low incidence of HER2 subtype as compared to the other subtypes. Conclusions: The luminal B and HER2 subtypes were prevalent in carcinomas with MPC. This result explains the poor prognosis of breast carcinomas with an MPC pattern.
Abstract
Background: Micropapillary carcinoma (MPC) is known to have a worse prognosis than the other subtypes of breast cancer. Occasionally, MPC is observed in association with invasive ductal carcinoma not otherwise specified (IDC NOS), as well as mucinous carcinoma. Methods: We examined the immunohistochemical expression of an estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) in 127 cases of surgically resected MPC or IDC NOS with MPC. Further, we classified these cases based on their immunohistochemical profile. Results: Among the IDC NOS with MPC cases, 47 were luminal A (62.7%), 10 were luminal B (13.3%), and 9 were HER2 (12.0%). The MPC cases included 4 luminal A (50.0%), 2 luminal B (25.0%) and 1 HER2 (12.5%) subtypes. Of the mucinous carcinomas with MPC, 4 were grouped as luminal A (57.1%), 1 as luminal B (14.3%), and 2 as HER2 (28.6%) subtypes. However, among the mucinous carcinomas, 33 were categorized as luminal A (89.2%), 3 as luminal B (8.1%), and 1 as HER2 (2.7%) subtype, indicating a low incidence of HER2 subtype as compared to the other subtypes. Conclusions: The luminal B and HER2 subtypes were prevalent in carcinomas with MPC. This result explains the poor prognosis of breast carcinomas with an MPC pattern.
참고문헌 (26)
- La Vecchia C, "Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975", Ann Oncol, 21, pp.1323~1360 (2010)
- Kuroda H, "Clinical and pathologic features of invasive micropapillary carcinoma", Breast Cancer, 11, pp.169~174 (2004)
- Bal A, "Prognostic significance of micropapillary pattern in pure mucinous carcinoma of the breast", Int J Surg Pathol, 16, pp.251~256 (2008)
- Shet T, "Presence of a micropapillary pattern in mucinous carcinomas of the breast and its impact on the clinical behavior", Breast J, 14, pp.412~420 (2008)
- Carey LA, "Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study", JAMA, 295, pp.2492~2502 (2006)
- Zekioglu O, "Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma", Histopathology, 44, pp.18~23 (2004)
- Chen L, "Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases", Int J Surg Pathol, 16, pp.155~163 (2008)
- Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
- Roh JH, "Micropapillary carcinoma of stomach: a clinicopathologic and immunohistochemical study of 11 cases", Am J Surg Pathol, 34, pp.1139~1146 (2010)
- Moritani S, "Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis", Hum Pathol, 39, pp.666~671 (2008)
- Kawakami T, "Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors", Mod Pathol, 20, pp.514~521 (2007)
- Kuroda N, "Invasive micropapillary carcinoma of the colon: an immunohistochemical study", Med Mol Morphol, 40, pp.226~230 (2007)
- Wen P, "Invasive micropapillary carcinoma of the sigmoid colon: distinct morphology and aggressive behavior", Int J Clin Exp Pathol, 1, pp.457~460 (2008)
- Kamat AM, "The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma", J Urol, 175(3 Pt 1), pp.881~885 (2006)
- Lopez-Beltran A, "Invasive micropapillary urothelial carcinoma of the bladder", Hum Pathol, 41, pp.1159~1164 (2010)
- Slamon DJ, "Human breast cancer: correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
- Luna-Moré S, "Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast: review of 68 cases with follow-up of 54", Pathol Res Pract, 196, pp.35~39 (2000)
- Tamimi RM, "Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer", Breast Cancer Res, 10, pp.R67~ (2008)
- Shibuta K, "The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer", Breast Cancer (2010)
- Weigelt B, "Refinement of breast cancer classification by molecular characterization of histological special types", J Pathol, 216, pp.141~150 (2008)
- De la Cruz C, "Invasive micropapillary carcinoma of the breast: clinicopathological and immunohistochemical study", Pathol Int, 54, pp.90~96 (2004)
- Kuroda H, "Overexpression of Her2", neu, estrogen and progesterone receptors in invasive micropapillary carcinoma of the breast, 2004, pp.11, 301~306
- Kim MJ, "Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary carcinoma component", Arch Pathol Lab Med, 129, pp.1277~1282 (2005)
- Marchiò C, "Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast", J Pathol, 215, pp.398~410 (2008)
- Varga Z, "Preferential HER-2", neu overexpression and, Histopathology, pp.2004, 44[DOI]
- Luna-Moré S, "Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas", Pathol Res Pract, 192, pp.27~32 (1996)